Skip to Content
  • Changes in NIH Grant Policy?

    There are some pretty big funding changes being proposed at the NIH that many people may not be aware of. A concerned NIH grantee has sent along some links and… Read More
  • Aggregator Aggravation, In a New Way

    Experienced drug discovery folks, particularly those that work early on in the process, will tell you that aggregation is one of the most common sources of fals… Read More
  • More Spring-Loaded Reagents

    I wrote just about this time last year about a new “strain-release” bond forming reaction system from the Baran group at Scripps. Now they’ve… Read More
  • The Flightosome

    I got this diagram from Arjun Raj‘s Twitter feed, and I think I enjoy it a bit more every time I see it. Some of that is because it’s a big part of… Read More
  • Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natur… Read More
  • Watson and Pfizer

    I have wondered several times around here about how (and if) IBM’s Watson platform is going to be able to help out with drug discovery, and it looks like… Read More
  • Nitration Isn’t So Simple

    OK, let’s get physical organic here for a little while. For those outside the field, physical organic chemistry is the branch that studies how and why the… Read More
  • Pfizer Bails on PCSK9 antibodies

    Well, no sooner do I mention that Pfizer has a PCSK9 antibody coming along in the clinic then they don’t. Not any more. The company has announced that the… Read More
  • Inside Theranos: Yikes

    I always wondered what sort of place Theranos must be (have been) to work at, and now this piece at Vanity Fair answers the question: hellish. The treatment of… Read More
Page 1 of 1012345...10...Last »